Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months

Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.

Drug Resistant Epilepsy

Cholecalciferol

Placebo Oral

Vitamine D in Drug Resistant Epilepsy

Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy

Total score at baseline and after Vitamin D treatment (range 0-200; higher values=worse outcome)

Total score at baseline and after Vitamin D treatment (range 0-42; higher values=worse outcome)

Global score at baseline and after Vitamin D treatment (the higher score, the better outcome)

Vitamin D levels and percentage reduction in the seizure frequency compared to the reference period

Vitamin D level and type of AED (enzyme inducer versus non enzyme inducer drugs)

Vitamin D level and dose of AED (low dose versus high dose of enzyme inducer drugs)

Responder rate after Vitamin D treatment. Percentage of patients having a reduction of at least 50% of the seizure frequency

Percentage of patients without any seizure (seizure freedom)

Responder rate in focal and generalized epilepsy

Percentage of reduction of secondary generalized seizures and epileptic falls in respect to the reference period

Centre Hospitalier St Anne

APHP

FFRE

LFCE

Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not

Colloids, including albumin, gelatines, starch any other synthetic colloids

Critical Illness

Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay

Crystalloids

Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay

Colloids

Any crystalloids given for correction of hypovolemia during all ICU stay

Any colloids given for correction of hypovolemia during all ICU stay

Hôpital Erasme

CHU de Sherbrooke-Höpital Fleurimont

Hôpital Charles LeMoyne

CH d'Angers

Centre Hospitalier d'Annecy

CH Joseph Imbert

CH d'Arpajon

CHG de Bastia

Hôpital Avicenne

CH Pellegrin Tripode

Hôpital Cavale Blanche

Chg Briancon

HIA Percy

Hôpital A. Beclere

Hôpital Corbeil Essonnes

Hôpital Henri Mondor

Hôpital Général

CH Dourdan

Centre Hospitalier d'Etampes

Hôpital de FREYMING-MERLEBACH

Hôpital Raymond Poincaré

Hôpital A. Mignot

CHU Liege

Hôpital Claude Huriez

CH Dupuytren

Centre Régional Léon Bernard

Hôpital Louis Pradel

CH MEAUX

Hôpital Saint Eloi

Centre Hospitalier de Mulhouse

Hôpital Central

Hôpital Central NANCY

Polyclinique de Gentilly

CHRG d'Orléans

HEGP

Hôpital Bichat Claude Bernard

Hôpital Bicêtre

Hôpital la Pitié Salpétrière

Hôpital Lariboisière

Hôpital Saint Louis

Hôpital TENON

Hôtel Dieu

CHU de Bordeaux

Chu Lyon Sud

CHI Poissy

CHU de Poitiers

Centre Hospitalier R. Dubos

CH Claude Galien

Chu Reims

CHU Rennes

CH Victor Provo

Hôpital Charles Nicolle

Centre Cardiologique du Nord

CHI Saint Germain en Laye

CH Mémorial SAINT LO

CHG de SOISSONS

Hôpital Civil

Hôpital Hautepierre

CHR Bel Air

CHU Toulouse

CHG Valence

CHU Brabois Nancy

Hôpital T Sfar

Chu Bourguiba

Hôpital A Mami

Homerton University Hospital

Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients

CRISTAL: Colloids Compared to Crystalloids in Fluid Resuscitation of Critically Ill Patients: A Multinational Randomised Controlled Trial

Djillali Annane

Professor in medicine

University of Versailles

Assistance Publique - Hôpitaux de Paris

Crohn Disease

Capsule endoscopy for small and large bowel to assess Crohn's disease activity.

PillCamTM Crohn's capsule

MRI scan of small bowel to assess small bowel Crohn's disease activity.

Magnetic resonance enterography

Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.

Ileo-colonoscopy

PANenteric Crohn's Capsule Versus Ileo-Colonoscopy and Scan Study

To assess the rate of macroscopically detectable disease or "positive yields" by the PillCamTM Crohn's capsule compared to ileo-colonoscopy and magnetic resonance enterography in patients with an established diagnosis of Crohn's disease.

To determine the correlation of small bowel scoring systems i.e. between the Lewis score for PillCamTM Crohn's capsule and the small bowel score of Magnetic Resonance Enterography Global Score (MEGS) and the small bowel Magnetic Resonance Index of Activity (MaRIA) score for MRE.

To determine the correlation of colonic scoring systems i.e. between the colonic score of Capsule Endoscopy Crohn's Disease Activity Index for the Small Bowel and Colon (CECDAIic) for PillCamTM Crohn's capsule and the Simple Endoscopic Score for Crohn's Disease (SES-CD) for ileo-colonoscopy.

To compare the positive diagnostic yield of PillCamTM Crohn's capsule with clinical severity based on the Harvey-Bradshaw Index.

To compare the positive diagnostic yield of PillCamTM Crohn's capsule with patient quality of life based on the short Inflammatory Bowel Disease-Questionnaire (IBD-Q) score.

Qualitative assessment via telephone interview to evaluate a subset of patients based on their experience of undergoing PillCamTM Crohn's capsule endoscopy, MRE and ileo-colonoscopy.

paris/náusea

Vitamine D in Drug Resistant Epilepsy

Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients

PANenteric Crohn's Capsule Versus Ileo-Colonoscopy and Scan Study

La base de datos de hierbas medicinales más completa respaldada por la ciencia